Beyond age: Why genetics and lifestyle matter in prostate cancer risk

Prostate cancer is the fourth most common cancer among men in India. Often symptomless in its early stages, it is highly treatable when detected promptly. Firstpost shares expert insights on symptoms, diagnosis, risk factors, and the crucial role of early screening. read more
Prostate cancer , one of the most common cancers affecting men, has been steadily increasing in India particularly in urban areas. Though often symptomless in its early stages, the disease can lead to serious complications if not detected and treated in time. With awareness still limited among many men, understanding the symptoms, risk factors and treatment options is crucial.
Firstpost spoke to Dr Trinanjan Basu, HOD & Senior Consultant—Radiation Oncology at HCG Cancer Centre (Borivali) to learn more about prostate cancer's prevalence, diagnosis and how timely intervention can improve survival rates.
STORY CONTINUES BELOW THIS AD
What is prostate cancer and how prevalent is it in men in India?
Dr Basu: Prostate cancer affects the prostate gland, a part of the male reproductive system. It is a male-specific cancer, typically occurring in older men. In India, it ranks as the fourth most common cancer among men, especially in metropolitan cities. According to cancer registries, the incidence is about 10 cases per 1 lakh male population in urban areas, with a consistent upward trend over the past decade.
Watch also: Former US President Joe Biden Diagnosed with Aggressive Prostate Cancer | Firstpost America | N18G
What are the initial signs and symptoms of prostate cancer ?
Dr Basu: Early-stage prostate cancer is usually asymptomatic, making regular screening essential. When symptoms do appear, they often involve changes in urinary habits, such as increased frequency or urgency, difficulty in urination, blood in urine, nighttime urination, and reduced bladder capacity. These symptoms should never be ignored, especially in elderly men.
How is prostate cancer diagnosed? What tests are typically performed?
Dr Basu: Diagnosis typically begins with a Digital Rectal Examination (DRE) to check for abnormalities in the prostate. If suspicion arises, further tests include MRI of the prostate and a prostate biopsy to confirm cancer presence. The Prostate-Specific Antigen (PSA) blood test is commonly used for initial screening and monitoring. These tests help determine the stage and aggressiveness of the cancer.
What are the key risk factors for developing prostate cancer?
Dr Basu: Age is a major risk factor, with most diagnoses occurring between ages 70 and 75. Genetics also play a role—men with a family history of prostate cancer or known BRCA gene mutations are at higher risk and should consider early screening starting between ages 40 and 45. While lifestyle and ethnicity influence risk, they were not specifically addressed here.
What happens if prostate cancer is left untreated?
Dr Basu: Without diagnosis or treatment, prostate cancer can progress from a localized condition to advanced or metastatic stages, severely worsening the prognosis. Once it reaches the hormone-refractory or castration-resistant phase, treatment options decline and the average survival drops to 15–20 months. Advanced stages are associated with serious complications and reduced quality of life.
What treatment options are available at different stages of prostate cancer?
Dr Basu: Treatment varies by stage and risk category. Active surveillance may be appropriate for very early-stage (Stage 1) cancer, especially in older men. For Stage 2 and beyond, options include surgery, radiotherapy, hormone therapy, or combinations thereof. Chemotherapy may be used in advanced cases. Early diagnosis and timely treatment are critical for better outcomes.
Can prostate cancer be cured? What are the survival rates?
Dr Basu: Prostate cancer is highly curable, particularly when detected early. Stage 1 patients are often monitored without immediate treatment. Stage 2 has about an 85% cure rate, Stage 3 around 70%, and Stage 4 less than 40%. Hormone sensitivity also affects outcomes; once cancer becomes castration-resistant, treatment efficacy declines significantly.
How does age affect treatment decisions and outcomes?
Dr Basu: Age is a key factor in treatment planning and prognosis. With a median diagnosis age of 70–75, screening beyond 70 can still be beneficial. Younger patients with early-stage disease generally respond better to treatment and have longer survival, while older patients may receive more conservative treatment depending on overall health and comorbidities.
What role do lifestyle factors play in preventing or reducing recurrence of prostate cancer?
Dr Basu: Maintaining a healthy lifestyle is important for overall health, although prostate cancer is not directly linked to diet as some other cancers are. Diets high in red meat, fats, or those causing hormonal imbalance, such as low zinc intake or high saturated fats may increase risk and should be avoided. Exercise, combining aerobic and anaerobic activities, improves quality of life and helps counter the side effects of hormone therapy like cholesterol imbalance and bone density loss. Higher body mass index, especially abdominal obesity, is associated with increased risk due to hormonal effects. Overall, a balanced diet, regular physical activity, and healthy weight management are key preventive strategies.
How important is early detection and how can men be encouraged to get screened?
Dr Basu: Early detection is crucial for high cure rates and avoiding aggressive treatments. The PSA blood test should be recommended for all men over 50, and earlier (around 40–45 years) for those with a family history or genetic risks. Raising public awareness, encouraging regular health check-ups, and educating men about symptoms and screening methods can significantly improve early diagnosis and save lives.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

First Post

a day ago

• First Post

Dr explains: How to spot early Alzheimer's symptoms and why younger adults should care too

Alzheimer's disease isn't just a condition of old age. Subtle symptoms can appear earlier than expected and are often mistaken for routine forgetfulness. Firstpost spoke to an expert on how to recognise the red flags, distinguish the disease from normal ageing, and adopt preventive measures to protect brain health early. read more Alzheimer's disease, often thought to be a condition of old age, can begin far earlier than most people realise and the signs aren't always as obvious as memory loss. With rising stress levels, lifestyle diseases, and increasing life expectancy, the burden of Alzheimer's in India is expected to climb sharply in the coming decades. Despite this, many people remain unaware of its early warning signs, confusing them with routine forgetfulness or age-related decline. STORY CONTINUES BELOW THIS AD Firstpost spoke to Dr Pooja Anand, Associate Consultant – Neurology at Paras Health (Gurugram) to shed light on how Alzheimer's differs from normal aging, the red flags to watch for and how prevention can start well before retirement age. What exactly is Alzheimer's disease, and how is it typically identified in its early stages? Alzheimer's disease is a progressive neurodegenerative disorder that primarily impairs memory and cognitive function. In its early stages, it often manifests as subtle memory lapses such as forgetting names or recent events—that gradually become more pronounced. These changes go beyond ordinary forgetfulness and begin to interfere with daily life and routine functioning. Diagnosis typically involves clinical evaluations, cognitive testing, brain imaging, and in some cases, biomarker testing. How does Alzheimer's differ from normal age-related memory loss or forgetfulness? It's important to distinguish Alzheimer's from normal aging. Occasional forgetfulness—like misplacing keys or struggling to recall a name but remembering it later—is common with age. However, Alzheimer's involves persistent memory loss, confusion, and difficulty with reasoning or problem-solving. People may get lost in familiar places or have trouble following conversations—warning signs that extend beyond normal aging. At what age does the risk of developing Alzheimer's disease begin to significantly increase? The risk of Alzheimer's rises significantly after the age of 65. That said, it's not exclusively a disease of old age. Early-onset Alzheimer's, though rare, can appear in individuals as young as their 40s or 50s. As age is the strongest risk factor, cases rise sharply among people in their 70s and 80s. What are some early warning signs or red flags that people should look out for in Alzheimer's or other forms of dementia? Early warning signs include memory loss that disrupts daily life, trouble completing familiar tasks, confusion about time or place, and difficulty understanding visual images or spatial relationships. Changes in mood, personality, or social withdrawal can also be indicators. Persistent or worsening symptoms should prompt further medical assessment. What are some common myths or misconceptions surrounding Alzheimer's disease? A common myth is that Alzheimer's is simply part of normal aging—which it is not. Another misconception is that only the elderly are affected, when in fact early-onset cases do exist. There's also a belief that nothing can be done after diagnosis. In reality, early intervention, appropriate support, and available treatments can help manage symptoms and improve quality of life. How much of a concern is early-onset Alzheimer's, and how frequently does it occur compared to cases in older adults? Early-onset Alzheimer's is relatively uncommon, accounting for 5–10% of all cases. However, it is particularly concerning as it strikes during an individual's working years and can be more difficult to diagnose due to its unexpected timing. In some cases, the disease also progresses more aggressively, making early detection and treatment crucial. Does the treatment approach differ between early-onset and late-onset Alzheimer's patients? Core treatment strategies—managing symptoms, slowing disease progression, and supporting patients and caregivers—are generally the same. However, early-onset patients often face additional challenges related to employment, finances, and parenting, requiring specialised psychosocial support and care planning tailored to their unique circumstances. Is there evidence linking cardiovascular health—like heart disease or hypertension—to a higher risk of Alzheimer's, especially among younger adults in India? Yes, growing evidence suggests a strong link between cardiovascular and brain health. Conditions like hypertension, diabetes, and obesity—which are increasingly common among younger adults in India—can raise the risk of cognitive decline. Poor cardiovascular health can reduce blood flow to the brain, which may contribute to Alzheimer's and other dementias over time. What lifestyle habits or preventive measures can individuals adopt to reduce their risk of developing Alzheimer's disease later in life? A brain-healthy lifestyle can play a major role in prevention. This includes regular physical exercise, a balanced diet rich in fruits, vegetables, and healthy fats (such as the Mediterranean diet), mental stimulation, good quality sleep, and social engagement. Managing stress, avoiding smoking, and controlling blood pressure and blood sugar are also key. In short, what benefits the heart also benefits the brain.

First Post

a day ago

• First Post

Fighting a genetic enemy: How sickle cell disease quietly impacts childhood in India

Sickle cell disease affects thousands of Indian children, yet its most dangerous complications often go unnoticed. Experts tell Firstpost that what begins as a blood disorder can escalate into serious, chronic health problems if not diagnosed and managed early. read more Sickle cell disease (SCD) remains one of the most under-recognised genetic conditions affecting children in India with profound long-term effects on the brain, organs, growth and quality of life. While many associate the disease primarily with painful episodes, experts say the damage often begins quietly, early in life, and worsens over time without timely intervention. Firstpost spoke to leading paediatric and haematology experts — Dr. Shweta Bansal, Head - Paediatric Haemato Oncology & Paediatric BMT, Medical Oncology, Sir H.N. Reliance Foundation Hospital; Dr. Gaurav Dixit, Associate Director, Haemato-oncology & Bone Marrow Transplant at Paras Health, Gurugram; and Dr. Atique Ahemad, Newborn & Child Specialist, Saifee Hospital, Mumbai to understand the complex burden of this disease and how parents and physicians can intervene early. STORY CONTINUES BELOW THIS AD How sickle cell affects the brain — often without warning According to Dr. Shweta Bansal, sickle cell disease significantly increases the risk of both overt and silent strokes in children. 'Due to the sickle-shaped red blood cells, the brain's blood vessels can get blocked, depriving areas of the brain of oxygen. About 10% of children with SCD experience a stroke by age 14,' she said. Yet the bigger threat may be silent strokes which occur in nearly 1 in 4 school-age children with SCD. These don't show immediate symptoms but can impair memory, learning, attention and behaviour. 'We use Transcranial Doppler (TCD) ultrasounds to measure blood flow in the brain. If the velocity is high, it indicates stroke risk and we start preventive therapy. MRIs also help identify silent strokes,' Dr. Bansal added. Early signs and complications in children Dr. Atique Ahemad said that while infants with SCD may remain asymptomatic in the first 6–7 months due to protective fetal haemoglobin, symptoms emerge soon after. These include pallor, delayed growth, hand-foot swelling (dactylitis), and frequent pain episodes. 'Children often cry excessively due to pain. These crises can start by the age of six and affect various body parts, arms, legs, back and chest leading to long-term damage,' he says. Pain crises, or vaso-occlusive crises (VOCs), are particularly harmful. Dr. Gaurav Dixit said that each episode deprives vital organs of oxygen, progressively damaging the kidneys, brain, lungs, liver and heart. 'Frequent VOCs significantly increase the risk of chronic organ dysfunction, stroke, pulmonary hypertension, and early mortality,' he warned. How pain and infections are managed Pain in SCD isn't just distressing — it's also diagnostically challenging. 'There is no scan to quantify pain. The patient's words are the only reliable indicator,' Dr. Ahemad said, emphasising the need for compassionate and responsive care. Dr. Bansal outlines a two-pronged strategy: preventing crises and managing acute attacks. Preventive measures include hydration, avoiding extreme temperatures, and reducing physical or emotional stress. For mild pain, paracetamol or ibuprofen suffices but severe cases may require hospital-based morphine treatment. Preventing infections is equally critical, as SCD weakens the spleen. Dr. Bansal advises routine handwashing, safe food hygiene, vaccinations (including annual flu and pneumococcal vaccines), and daily penicillin till age 5 for high-risk children. 'With regular check-ups and support, these children can lead full lives,' she says. Hydroxyurea: A gamechanger in disease management One of the most effective tools in managing SCD is hydroxyurea. Dr. Bansal explains: 'It helps produce more fetal haemoglobin, reducing red cell sickling. This means 50–70% fewer pain crises, fewer transfusions, better school attendance and significantly extended life expectancy, even in rural areas.' Importantly, she said that hydroxyurea is safe for long-term use, including in children older than 9 months. Bone Marrow Transplant: A potential cure — for a few While hydroxyurea helps manage symptoms, a bone marrow transplant (BMT) remains the only proven cure. However, it is only an option for a select group of patients. 'Children below 16 with a perfectly matched sibling donor and severe SCD complications — like stroke, lung disease, organ damage, or frequent crises — are considered eligible,' said Dr. Bansal. BMT carries risks and is generally reserved for the most severely affected cases. Research is ongoing into alternatives such as half-matched donors and gene therapies. STORY CONTINUES BELOW THIS AD Hidden organ damage and long-term risks Dr. Dixit reiterates the toll VOCs take on the body over time. 'Organ systems, kidneys, heart, lungs and brain deteriorate silently with each crisis. Chronic kidney disease, pulmonary hypertension, and heart failure are major causes of reduced life expectancy in adult SCD patients,' he said. Dr. Ahemad lists stroke, acute chest syndrome, retinal damage, and splenic or hepatic sequestration among the most severe complications seen in adults. 'Long-term pain, bone necrosis and arthritis are common too. Early management of VOCs is key to preserving organ health and improving life quality,' he advised.

Indian Express

5 days ago

• Indian Express

Hope for stomach, brain cancer? Cancer-fighting immune therapy works on solid tumours in early trials

Despite a failed bone marrow transplant, Delhi's Dr (Col) VK Gupta beat his blood cancer after receiving CAR T-cell therapy at Tata Memorial Hospital. Not only did he recover, he was able to go back to work in his outpatient clinic. He is among those with blood cancer who has benefitted from this cutting edge cancer treatment that re-engineers the body's own immune cells, enabling them to fight the cancerous ones. Can this therapy now work for solid and hard-to-treat tumours as well? Earlier this month, there was good news on this front with two studies indicating increase in life span. Positive results from the first ever phase II trial of CAR T-cell therapy for solid cancers — those in the form of gastrointestinal tumours — were published from China. Another early study on the impact of a double target CAR T-cell therapy on a very difficult-to-treat brain cancer was also published in the US. 'With so many people working on the problem, it is possible that we could soon see CAR T-cell therapy for solid cancers. While the results are unlikely to be as dramatic as we have seen with blood cancers, any hope is good when survival otherwise is just a couple of months,' says Dr Hasmukh Jain, a specialist of blood cancers from Tata Memorial Hospital. He collaborated with the IIT Bombay team that developed the country's first CAR T-cell therapy. CAR T-cell therapy essentially uses a cancer patient's own immune T-cells and engineers them in a laboratory to add receptors that can bind specifically with the cancer cells only. These engineered cells are then multiplied and infused in the patient. Usually, the cancerous cells have the ability to hide from the unmodified T-cells. However, with the new receptors on the T-cells, they cannot. The body's immune system then kills the cancer cells. This, experts say, is because it is much more difficult to target solid cancers than blood cancers. 'One of the biggest problems with CAR T-cell therapy for solid cancers is that there aren't enough good targets. Several of the solid cancer markers are also found on normal, healthy cells, so they cannot be used. There have been cases of pulmonary toxicity with therapies whose target was expressed in small quantities in the lungs. Or, take for example, the BRCA gene mutations in breast cancers; these are expressed by other healthy cells as well,' says Dr Mayank Singh, associate professor of medical oncology at AIIMS-New Delhi. Another challenge is that the same type of cancer may be molecularly very different in different patients — or even within the same patient — making it extremely difficult to find a suitable target for CAR T. Besides, solid tumours are a more complex disease, says Dr Jain. 'Unlike blood cancers, other cancers are not in the blood where the T-cells are. So, they have to find the tumour and enter it. This is difficult as the T- cells are not able to effectively penetrate the tumour microenvironment or the immediate area round the tumour,' he explains. This is hostile towards immune cells and can deactivate them, including the modified T-cells given to patients. The phase II study from China showed that the outcome was better with the new CAR T therapy as compared to the therapy generally prescribed by the physician. Patients with gastrointestinal cancers carrying a specific mutation called CLDN18.2 — having received two unsuccessful treatments previously — were given either the new therapy or existing treatments. The study found that 35 per cent of the patients given the new treatment responded as compared to 4 per cent of those on existing treatments. Those on the new therapy also lived 2.4 months longer on average as compared to the control group. Another new CAR T-cell therapy, which used two targets instead for a very difficult to treat brain tumour called glioblastoma, showed promise in a trial conducted at University of Pennsylvania. The tumours became smaller in nearly two-thirds of the patients with recurrent glioblastoma who received the novel therapy. And, several of the patients have already lived 12 months or longer, which is significant considering that people with this type of cancer typically survive only for six to ten months. Importantly, the researchers also found evidence to suggest that the modified T-cells remained in the patients' immune system and continued to prevent tumour growth over time. Experts say that studies on brain and spinal cancers called gliomas and those targeting CLDN18.2 are probably at the most advanced stages of development and may be approved within a few years. 'Now, researchers are using AI to identify suitable targets for CAR T therapies. This is the reason for the recent increase in trials,' says Dr Singh. The IIT Bombay-incubated start-up ImmunoACT is also working on a therapy that can work on brain and nerve cell cancers called glioblastoma and neuroblastoma. Another therapy that it is pursuing will work on the gastric and gastroesophageal junction cancers — the same cancers as the Chinese trial looked at. Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government's management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country's space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University's Dart Centre. Dutt has a Bachelor's Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More